Secondary prevention medications for cardiovascular diseases are underused globally and additional strategies to increase their use are needed to improve management and r educe premature mortality rates, according to results from the PURE study published in JACC. The landmark multinational, community-based study observed more than 11,000 participants with diagnosed cardiovascular disease from 17 countries over a median follow-up of 12 years. Median age at baseline was 58 years, and 52.9% of participants